Bank of New York Mellon
XFOR icon

Bank of New York Mellon’s X4 Pharmaceuticals XFOR Stock Holding History

Bank of New York Mellon’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$917K Buy
+196,340
New +$806K ﹤0.01% 3417
2025
Q2 		– Sell
-11,492
Closed -$81.5K – 4280
2025
Q1 		$81.5K Hold
11,492
– – ﹤0.01% 4024
2024
Q4 		$253K Hold
11,492
– – ﹤0.01% 3864
2024
Q3 		$231K Sell
11,492
-4,154
-27% -$86.7K ﹤0.01% 3868
2024
Q2 		$272K Buy
15,646
+4,447
+40% +$145K ﹤0.01% 3855
2024
Q1 		$467K Sell
11,199
-333
-3% -$9.27K ﹤0.01% 3564
2023
Q4 		$290K Sell
11,532
-4,291
-27% -$104K ﹤0.01% 3811
2023
Q3 		$517K Sell
15,823
-118
-0.7% -$5.15K ﹤0.01% 3527
2023
Q2 		$928K Buy
15,941
+10,235
+179% +$526K ﹤0.01% 3235
2023
Q1 		$149K Hold
5,706
– – ﹤0.01% 4005
2022
Q4 		$170K Buy
5,706
+1,049
+23% +$49.7K ﹤0.01% 4017
2022
Q3 		$239K Hold
4,657
– – ﹤0.01% 3943
2022
Q2 		$135K Sell
4,657
-30
-0.6% -$1.14K ﹤0.01% 4166
2022
Q1 		$246K Buy
+4,687
New +$269K ﹤0.01% 4130
2021
Q2 		– Sell
-1,812
Closed -$468K – 4478
2021
Q1 		$468K Buy
1,812
+69
+4% +$18.1K ﹤0.01% 3721
2020
Q4 		$336K Buy
1,743
+105
+6% +$20.6K ﹤0.01% 3785
2020
Q3 		$333K Buy
1,638
+41
+3% +$9.83K ﹤0.01% 3680
2020
Q2 		$447K Buy
1,597
+299
+23% +$81.9K ﹤0.01% 3536
2020
Q1 		$389K Buy
1,298
+208
+19% +$59K ﹤0.01% 3490
2019
Q4 		$350K Buy
1,090
+188
+21% +$67.4K ﹤0.01% 3743
2019
Q3 		$344K Buy
902
+436
+94% +$173K ﹤0.01% 3727
2019
Q2 		$210K Buy
+466
New +$237K ﹤0.01% 3910
2019
Q1 		– Sell
-141
Closed -$59K – 4262
2018
Q4 		$59K Buy
141
+55
+64% +$21K ﹤0.01% 4041
2018
Q3 		$25K Sell
86
-1
-1% -$424 ﹤0.01% 4196
2018
Q2 		$57K Buy
87
+18
+26% +$59K ﹤0.01% 4076
2018
Q1 		$283K Buy
+69
New +$201K ﹤0.01% 3821

Other funds holding XFOR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Bank of New York Mellon's XFOR Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 196,340 shares worth $917K. The stake represents ﹤0.01% of the portfolio and ranks #3417 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in XFOR as recently as Q1 2025.

Bank of New York Mellon first reported a position in XFOR in Q1 2018 and has held it in 26 quarters since. The position peaked at $928K in Q2 2023. 19 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Bank of New York Mellon held 196,340 shares of X4 Pharmaceuticals worth $917K as of Q2 2026.
  • X4 Pharmaceuticals was a new Bank of New York Mellon position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3417 holding.
  • Bank of New York Mellon first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 26 quarters since.
  • Bank of New York Mellon's X4 Pharmaceuticals position peaked at $928K in Q2 2023.
  • 19 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.